Tags Archives: activated clotting time

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) is a critical support modality for patients with reversible cardiopulmonary failure. Despite its benefits, ECMO is associated with neurologic adverse events (NAE), including seizures..

Perfusfind S.L.

Abstract Background Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder that is frequently associated with systemic lupus erythematosus (SLE). Cardiac surgery in patients with APS presents unique challenges because activated..

Perfusfind S.L.

Abstract To prevent uncontrolled activation of the hemostatic system and thrombin formation that could be triggered by cardiopulmonary bypass (CPB), unfractionated heparin (hereinafter heparin) is administered to induce profound anticoagulation. Effective..

Perfusfind S.L.

Abstract Background: Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to prevent clotting, typically using unfractionated heparin (UFH). However, anticoagulation carries a bleeding risk, necessitating monitoring. Activated clotting time (ACT) is..

Perfusfind S.L.

Abstract Objectives The present study was designed to investigate the equivalence of two target activated clotting time (ACT) values with regard to packed red blood cell (PRBC) transfusion in patients..

Perfusfind S.L.

Abstract Objectives To assess concordance between Hemochron Response (ACTr) and the three-activator device Hemochron Signature Elite (ACTe) in adult cardiac surgery patients. To evaluate the correlation between ACTe and anti-Xa..

Perfusfind S.L.

Abstract Introduction The recently recommended activated clotting time (ACT) to be maintained at the initiation of and during cardiopulmonary bypass (CPB) is ≥480 s. However, the post-unfractionated heparin (UFH) administration ACT..

Perfusfind S.L.

Abstract Objective: To assess the impact of post-protamine neutralisation activated clotting time (ACT) values on postoperative outcomes including chest drain output, transfusion requirements, and CICU stay, in patients undergoing cardiac surgery...

Perfusfind S.L.

Abstract Objective Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to reduce the risk of thromboembolic events. Despite its historic role, activated clotting time (ACT) remains a widely used heparin monitoring..

Perfusfind S.L.

Abstract OBJECTIVES Activated clotting time (ACT) is commonly used to monitor anticoagulation during cardiac surgeries. Final ACT values may be essential to predict postoperative bleeding and transfusions, although ideal values..

Perfusfind S.L.

Abstract In unfractionated heparin (UFH) monitoring during extracorporeal circulation, the traditional measures of activated clotting time (ACT) or activated partial thromboplastin time (APTT) may diverge, confounding anticoagulant adjustments. We aimed..

Perfusfind S.L.

Abstract Objective To retrospectively evaluate a  conservation approach to heparin reversal implemented during times of critical shortages. This approach was aimed at maintaining access to cardiac surgical services. Setting In-patient hospital..

Perfusfind S.L.

Abstract Introduction The activated clotting time (ACT) is a useful marker of unfractionated heparin (UFH) activity during cardiopulmonary bypass (CPB) or cardiac catheterization. Emicizumab, recently approved for bleeding prevention in..

Perfusfind S.L.

Abstract Background Sheep are a primary model of mechanical circulatory support (MCS) with heparin anticoagulation therapy frequently being monitored by activated clotting time (ACT) due to ease and cost. In..

Perfusfind S.L.

Abstract Introduction: The Activated Clotting Time (ACT) is commonly used to manage anticoagulation during cardiac surgery. The aim of this study was to compare the older manually operated Hemochron® Response and..

Perfusfind S.L.

Abstract Background: Cardiac surgery with extracorporeal circulation (ECC) requires the administration of anticoagulant drugs to maintain ACT ranges 400–600 seconds, which requires exhaustive coagulation monitoring for which various point-of-care devices..

Perfusfind S.L.

Abstract Background Recurrent observation of clot in the cardiopulmonary bypass circuit after the administration of a protamine test dose (PTD) prompted concern over the effects of PTDs on patient activated..

Perfusfind S.L.

Abstract Coagulation factor XII (fXII) is a plasma serine protease which belongs to the contact activation complex responsible for initiating the intrinsic coagulation pathway. fXII deficiency is a rare congenital..

Perfusfind S.L.

Abstract Factor XII (FXII) deficiency presents as a prolonged activated partial thromboplastin time (aPTT) but is not associated with clinically significant bleeding. Activated clotting time (ACT) is used routinely to..

Perfusfind S.L.

Abstract Background: Sonoclot is used to measure kaolin-based activated clotting time (kACT) for heparin management. Apart from measuring kACT, the device assesses the patient’s coagulation status by glass bead–activated tests..

Perfusfind S.L.

Objective Adequate , measured using  (ACT), is important during vascular and cardiac surgeries. Unfractionated heparin is the most common  used. The purpose of this analysis was to compare the i-STAT ACT (iACT) to..